Targeting Sur1-Trpm4 in sepsis-induced brain injury

靶向 Sur1-Trpm4 治疗脓毒症引起的脑损伤

基本信息

  • 批准号:
    10193865
  • 负责人:
  • 金额:
    $ 42.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-01 至 2023-09-30
  • 项目状态:
    已结题

项目摘要

Abstract Sepsis-induced brain injury is associated with an acute deterioration of mental status resulting in long-term cognitive deficits, increased functional morbidity, and diminution in the quality of life. There are limited diagnostic adjuncts, and as no targeted therapy is available, clinical management of septic patients with central nervous system (CNS) symptomatology is limited to the treatment of the underlying infection and optimal critical care management of shock. Therefore, a better understanding of the pathobiology is needed to define acute brain derangements in sepsis. We have previously demonstrated that magnetic resonance imaging of the brain in mice subjected to cecal ligation and puncture (CLP) was notable for an early and marked decrease in fractional anisotropy consistent with axonal swelling and/or axonal injury that was associated with microglial activation, and the subsequent development of cytotoxic edema as evidenced by a significant decrease in apparent diffusion coefficient values four days after CLP. Sulfonylurea receptor -1(Sur1) is a transmembrane receptor in the ATP binding cassette transporter family ABCC8 that upregulates after CNS injury to form an obligate association with Ca2+ sensitive transient receptor potential melastatin-4 (Trpm4) resulting in edema. Our preliminary data demonstrate the upregulation of Sur1 in murine septic brains. In this proposal, in aim 1, we will determine the temporal correlation between Sur1-Trpm4 expression and edema in the murine septic brain. In aim 2, we will determine if inhibition of Sur1-Trpm4 is associated with a decrease in microglial activation and edema, thereby leading to a subsequent improvement in outcomes in a murine CLP model of sepsis. The availability of an FDA approved Sur1-Trpm4 inhibitor further raises interest in this approach.
摘要 脓毒症引起的脑损伤与精神状态的急性恶化有关,导致长期 认知缺陷、功能性发病率增加和生活质量下降。存在有限 由于没有可用的靶向治疗,中心性败血症患者的临床管理 神经系统(CNS)疾病学仅限于治疗潜在感染, 休克的重症监护管理。因此,需要更好地理解病理生物学, 败血症导致的急性脑功能紊乱我们之前已经证明, 盲肠结扎和穿孔(CLP)小鼠的脑中, 在与轴突肿胀和/或轴突损伤一致的各向异性分数中, 活化,以及随后的细胞毒性水肿的发展,如通过显著降低 CLP后4天的表观扩散系数值。磺酰脲受体-1(Sur 1)是一种跨膜受体, ATP结合盒转运蛋白家族ABCC 8中的受体,其在CNS损伤后上调以形成 与Ca 2+敏感性瞬时受体电位melastatin-4(Trpm 4)的专性结合导致水肿。 我们的初步数据表明,在小鼠脓毒症脑中Sur 1的上调。在该提案的目标1中, 我们将在小鼠败血症模型中确定Sur 1-Trpm 4表达与水肿之间的时间相关性, 个脑袋在目标2中,我们将确定Sur 1-Trpm 4的抑制是否与小胶质细胞的减少有关。 激活和水肿,从而导致随后的改善结果在鼠CLP模型, 败血症FDA批准的Sur 1-Trpm 4抑制剂的可用性进一步提高了对这种方法的兴趣。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RAJESH K. ANEJA其他文献

RAJESH K. ANEJA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RAJESH K. ANEJA', 18)}}的其他基金

Regulation of LPS-mediated HMGB1 Release by Poly (ADP-ribose) Polymerase-1
聚 (ADP-核糖) 聚合酶 1 调节 LPS 介导的 HMGB1 释放
  • 批准号:
    8852631
  • 财政年份:
    2012
  • 资助金额:
    $ 42.5万
  • 项目类别:
Regulation of LPS-mediated HMGB1 Release by Poly (ADP-ribose) Polymerase-1
聚 (ADP-核糖) 聚合酶 1 调节 LPS 介导的 HMGB1 释放
  • 批准号:
    8468013
  • 财政年份:
    2012
  • 资助金额:
    $ 42.5万
  • 项目类别:
Regulation of LPS-mediated HMGB1 Release by Poly (ADP-ribose) Polymerase-1
聚 (ADP-核糖) 聚合酶 1 调节 LPS 介导的 HMGB1 释放
  • 批准号:
    9066511
  • 财政年份:
    2012
  • 资助金额:
    $ 42.5万
  • 项目类别:
Regulation of LPS-mediated HMGB1 Release by Poly (ADP-ribose) Polymerase-1
聚 (ADP-核糖) 聚合酶 1 调节 LPS 介导的 HMGB1 释放
  • 批准号:
    8293488
  • 财政年份:
    2012
  • 资助金额:
    $ 42.5万
  • 项目类别:
Regulation of LPS-mediated HMGB1 Release by Poly (ADP-ribose) Polymerase-1
聚 (ADP-核糖) 聚合酶 1 调节 LPS 介导的 HMGB1 释放
  • 批准号:
    8669994
  • 财政年份:
    2012
  • 资助金额:
    $ 42.5万
  • 项目类别:
PARP-1 is a Negative Modulator of the Heart Shock Response
PARP-1 是心脏休克反应的负调节剂
  • 批准号:
    7020897
  • 财政年份:
    2006
  • 资助金额:
    $ 42.5万
  • 项目类别:
PARP-1 is a Negative Modulator of the Heart Shock Response
PARP-1 是心脏休克反应的负调节剂
  • 批准号:
    7881755
  • 财政年份:
    2006
  • 资助金额:
    $ 42.5万
  • 项目类别:
PARP-1 is a Negative Modulator of the Heart Shock Response
PARP-1 是心脏休克反应的负调节剂
  • 批准号:
    7256506
  • 财政年份:
    2006
  • 资助金额:
    $ 42.5万
  • 项目类别:
PARP-1 is a Negative Modulator of the Heart Shock Response
PARP-1 是心脏休克反应的负调节剂
  • 批准号:
    7457944
  • 财政年份:
    2006
  • 资助金额:
    $ 42.5万
  • 项目类别:
PARP-1 is a Negative Modulator of the Heart Shock Response
PARP-1 是心脏休克反应的负调节剂
  • 批准号:
    7648257
  • 财政年份:
    2006
  • 资助金额:
    $ 42.5万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.5万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 42.5万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.5万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.5万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 42.5万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.5万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.5万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.5万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 42.5万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 42.5万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了